DAPI Logo
  1. Homepage
  2. Publikationen
  3. Über die Autoren
DAPI Logo
  1. Homepage
  2. Publikationen
  3. Über die Autoren
  • Über die Autoren
Deutsch Englisch
  • Contact
  • Imprint
  • Terms of Use
  • Data Protection
  • Login

KONTAKTINFORMATIONEN

Deutsches Arzneiprüfungsinstitut e. V. (DAPI)

Heidestraße 7
10557 Berlin

Tel. +49 30 / 40004-572
Fax +49 30 / 40004-573
Internet: www.dapi.de
E-Mail: info(at)dapi.de

KONTAKTINFORMATIONEN

Deutsches Arzneiprüfungsinstitut e. V. (DAPI)

Heidestraße 7
10557 Berlin

Tel. +49 30 / 40004-572
Fax +49 30 / 40004-573
Internet: www.dapi.de
E-Mail: info(at)dapi.de

Prof. Dr. med. Mahfoud, Felix

Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes

Publikationen

  • Use of fixed-dose combinations for cardiovascular indications from 2018 to 2023: a nationwide population-based study
  • Declining rates of fixed-dose combination pills for hypertension in Germany from 2016 to 2023
  • Hidden sodium in effervescent-tablet dietary supplements and over-the- counter drugs: a comparative cross-sectional study
  • Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021
  • Use of fixed‑dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia
  • Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany
  • “Dear Doctor” Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription
  • Changes in utilization of antihypertensive drugs following angiotensin receptor blocker product recalls in Germany
  • Impact On Antihypertensive Prescribing After The Dear Healthcare Professional Letter On Increased Risk Of Skin Cancer Related To Hydrochlorothiazide